Speaking at the Pharmabiotics event in Brussels, William Fusco, a gastroenterologist at Policlinico Universitario Agostino Gemelli, highlighted a recently published pilot study on post-infectious irritable bowel syndrome (IBS) framed within microbial precision medicine and biomarker-driven care. The study compared two patient groups: one treated according to the classic standard of care—an empiric, symptom-based approach—and another managed with a microbiome-informed strategy based on each patient’s specific gut dysbiosis, identified through gut microbiome testing (reported as 16S rRNA sequencing). While both groups showed clinical improvement, the microbiome-informed arm achieved a markedly greater benefit, described as a reduction of more than 150 points on the IBS severity score. Fusco emphasized that this is an early, proof-of-concept experience and that additional evidence is needed to consolidate and validate the method’s effectiveness, while expressing confidence that future results could be even stronger as the approach is refined.